According to filings with the U.S. Securities and Exchange Commission, PhotoniCare is raising up to $9,016,107.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About PhotoniCare
PhotoniCare was founded out of a shared passion to develop a superior solution for middle ear issues, primarily in children. With $10 billion spent annually to manage ear infections, and a documented 50% misdiagnosis rate for primary care physicians, current tools used to diagnose fluid in the middle ear fail to reliably interpret the patients condition. The FDA-cleared OtoSight Middle Ear Scope by PhotoniCare is a clinical diagnostic tool designed to eliminate subjectivity and speculation with a non-invasive and comprehensive assessment of middle ear fluid. OtoSight is indicated to not only visualize the presence of fluid, but also the fluids density, even in the presence of earwax. As a result, the simple-to-use OtoSight Middle Ear Scope has a 90+% reader accuracy in determining the presence or absence of fluid in the middle ear. Clinicians that have had an opportunity to use OtoSight consider it a game-changer. This is further demonstrated by multiple best-in-show product awards and over 20 supporting clinical publications. With OtoSight, PhotoniCare makes the otherwise invisible visible while effectively informing a successful treatment plan like never before.

To learn more about PhotoniCare, visit http://www.photoni.care/
PhotoniCare Linkedin Page: https://www.linkedin.com/company/photonicare/

Contact:
Cary Vance, President and Chief Executive Officer
866-411-3277
https://www.linkedin.com/in/cary-vance/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.